Chemotherapy: Metastatic Disease

作者: Kathryn M. Field , John R. Zalcberg

DOI: 10.1007/978-1-60761-567-5_12

关键词:

摘要: Metastatic colorectal cancer is one of the most common malignancies in Western world. Moreover, as this text so ably demonstrates, optimal management patients with rectal at any stage disease truly requires a multidisciplinary effort that, depending on illness, can involve colorectal, hepatobiliary, and thoracic surgeons, pathologists, radiologists, radiation oncologists, medical palliative care physicians, all playing important roles. The metastatic has become more challenging over past decade, treatment strategies locally advanced sometimes aimed cure rather than palliation. Additionally, number active anticancer agents including both chemotherapeutics targeted therapies which have demonstrated efficacy managing expanded considerably. Increasingly, are now able to be tailored toward an individual itself. In chapter, we will briefly provide overview epidemiology cancer, discuss past, present future used treat disease, some perspectives into future.

参考文章(180)
Gang Young, Charles Breedis, The blood supply of neoplasms in the liver. American Journal of Pathology. ,vol. 30, pp. 969- 977 ,(1954)
M J O'Connell, J A Mailliard, M J Kahn, J S Macdonald, D G Haller, R J Mayer, H S Wieand, Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. Journal of Clinical Oncology. ,vol. 15, pp. 246- 250 ,(1997) , 10.1200/JCO.1997.15.1.246
P Rougier, A Laplanche, M Huguier, J M Hay, J M Ollivier, J Escat, R Salmon, M Julien, J C Roullet Audy, D Gallot, Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. Journal of Clinical Oncology. ,vol. 10, pp. 1112- 1118 ,(1992) , 10.1200/JCO.1992.10.7.1112
M A Poon, M J O'Connell, C G Moertel, H S Wieand, S A Cullinan, L K Everson, J E Krook, J A Mailliard, J A Laurie, L K Tschetter, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. Journal of Clinical Oncology. ,vol. 7, pp. 1407- 1418 ,(1989) , 10.1200/JCO.1989.7.10.1407
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
A. Grothey, L. L. Hart, K. M. Rowland, R. H. Ansari, S. R. Alberts, N. M. Chowhan, A. Shpilsky, H. S. Hochster, Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial Journal of Clinical Oncology. ,vol. 26, pp. 4010- 4010 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4010
Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, Ralf Wong, Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Journal of Clinical Oncology. ,vol. 19, pp. 2282- 2292 ,(2001) , 10.1200/JCO.2001.19.8.2282